HGEN, company is still blinded from interim data?
Post# of 145184
From Seeking Alpha article today:
Lenzilumab had a clinically meaningful impact on patient recovery, with an estimated 37% more recoveries observed in the lenzilumab arm (HR of 1.37) vs. current standard of care (SoC).
And that one little comment, drove their stock up so far, 9% today!
We were not given that "positive" statistic on our 195 s/c interim analysis???
That specific stat for us, was probably nearer to 70% ......
What's going on in this goofy world?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)